Key Highlights

● Eli Lilly climbed to a 52-week high on Friday, October 30, 2026.

● There was no new company news; investors rotated into defensive sectors.

● Third-quarter Earnings Per Share of $7.48 beat the $6.61 estimate.

● Full-year Revenue guidance rose to a range of $91 billion to $92 billion.

Eli Lilly (NYSE:LLY) climbed to a 52-week high on Friday, October 30, 2026. There was no new company-specific news on the day. Instead, the shares gained as investors rotated into defensive sectors, according to market data, extending a rally that began with the company's third-quarter results on Thursday.

That report gave the stock plenty of fuel. Lilly posted earnings per share of $7.48, well ahead of the $6.61 analysts had expected. The Indianapolis-based drugmaker also raised its full-year revenue guidance to a range of $91 billion to $92 billion.

Lilly sells medicines for diabetes, obesity, cancer and other conditions. The stock also rose sharply over the week as a whole.

A record day for health care

The drugmaker had plenty of company. Health care stocks hit a record high on Friday, according to market data, as investors moved money out of semiconductors, artificial intelligence names and megacap technology. Regeneron Pharmaceuticals (NASDAQ:REGN) led the S&P 500 after a strong quarter, AbbVie (NYSE:ABBV) reached a 52-week high on a beat and raised outlook, and Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) also hit 52-week highs.

Health care was one of six S&P 500 sectors to finish higher, alongside energy, consumer staples, utilities, materials and real estate. The equal-weight S&P 500 fell far less than the cap-weighted benchmark, a sign that selling was concentrated in the largest technology companies.

The tech rout

The broader market had a rough day. The S&P 500 fell 140.32 points to 7,580.07. The Dow Jones Industrial Average lost 572.25 points to 51,770.31, and the Nasdaq Composite dropped 747.73 points to 25,437.00, its worst day since June 5. The Russell 2000 slid 47.37 points to 2,811.84.

Intel (NASDAQ:INTC) set off the decline after issuing a fourth-quarter revenue forecast of $15 billion to $16 billion, well below expectations, and warning of cash burn. The Philadelphia Semiconductor index sank to 10,688.80. Amazon (NASDAQ:AMZN)'s results, which showed trailing 12-month free Cash Flow of negative $42.4 billion, and continued losses in Alphabet (NASDAQ:GOOGL) after its record drop on Thursday deepened concerns about the cost of the AI buildout.

A senior market analyst said: "The message from investors is becoming clearer: strong AI Demand is no longer enough on its own."

Other pressures were at work too. West Texas Intermediate crude rose to $104.12 a barrel amid tensions near the Strait of Hormuz, crypto stocks fell after Binance was reportedly hacked for about $6.3 billion, and gold dropped to a 52-week low. The Federal Reserve left its benchmark rate range unchanged on Wednesday, but markets now expect a hike in December, and several Fed officials said on Friday that rates may need to go higher.

In that environment, investors favored companies with strong earnings visibility. Lilly, fresh off a report that beat forecasts and lifted its revenue outlook, fit that description.

What to watch

The key question is whether the rotation into health care holds. Investors will be watching whether money flows back into technology or keeps moving into defensive sectors.

Several events in the coming week could tip the balance. Apple (NASDAQ:AAPL) reports on Monday, November 2, followed by Pfizer and the midterm elections on Tuesday, November 3. The October jobs report on Friday, November 6, will shape expectations for a December rate hike, which in turn could influence demand for steady growers like Lilly.